

Accepted Manuscript

TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis

Changfeng Li, Yongjian Gao, Yongchao Li, Dayong Ding



PII: S0006-291X(17)30499-0

DOI: [10.1016/j.bbrc.2017.03.042](https://doi.org/10.1016/j.bbrc.2017.03.042)

Reference: YBBRC 37429

To appear in: *Biochemical and Biophysical Research Communications*

Received Date: 22 February 2017

Accepted Date: 12 March 2017

Please cite this article as: C. Li, Y. Gao, Y. Li, D. Ding, TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis, *Biochemical and Biophysical Research Communications* (2017), doi: 10.1016/j.bbrc.2017.03.042.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

TUG1 mediates methotrexate resistance in colorectal cancer via miR-186/CPEB2 axis

Changfeng Li¹, Yongjian Gao², Yongchao Li², Dayong Ding^{2,*}

¹ Department of Endoscopy Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China.

² Department of Gastrointestinal surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China.

* Corresponding author: Address: Department of Gastrointestinal surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China. E-mail: bile90566401130j@163.com.

Abstract

Colorectal cancer (CRC) is a common malignancy, most of which remain unresponsive to chemotherapy. Methotrexate (MTX) is one of the earliest cytotoxic drugs and serves as an anti-metabolite and anti-folate chemotherapy for various types of cancer. However, MTX resistance prevents its clinical application in cancer therapy. Thereby, overcoming the drug resistance is an alternative strategy to maximize the efficacy of MTX therapies in clinics. Long non-coding RNAs (lncRNAs) have gained widespread attention in recent years. More and more evidences have shown that lncRNAs play regulatory roles in various biological activities and disease progression including drug resistance in cancer cells. Here, we observed lncRNA TUG1 was associated to the MTX resistant in colorectal cancer cells. Firstly, quantitative analysis indicated that TUG1 was significantly increased in tumors which were resistant to

Download English Version:

<https://daneshyari.com/en/article/5505013>

Download Persian Version:

<https://daneshyari.com/article/5505013>

[Daneshyari.com](https://daneshyari.com)